PD-L1 expression on tumor cells—in addition to tumor mutational burden (TMB) and microsatellite instability (MSI) —is a widely used biomarker to predict the response to immunotherapy with antibodies blocking the PD-L1/PD1 axis [28]. This evidence concerns the gene CD274 and neoplasm.